This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06288/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06288/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/drug/DB06288/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB06288/identifier/pubchem-substance/
n6http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB06288/identifier/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06288/identifier/iuphar/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB06288/identifier/guide-to-pharmacology/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06288/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06288
rdf:type
n3:Drug
n3:description
Amisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.
n3:generalReferences
# Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12404702 # Moller HJ: Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1101-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14642970 # Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14575800 # Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002 Feb;159(2):180-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11823257
n3:group
investigational approved
n3:halfLife
Approximately 12 hours
n3:indication
Investigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression.
owl:sameAs
n6:DB06288 n21:DB06288
dcterms:title
Amisulpride
adms:identifier
n8:2159 n9:99443244 n10:963 n11:PA162565877 n12:Amisulpride n13:963 n14:2074 n15:DB06288
n3:mechanismOfAction
Amisulpride binds selectively to dopamine D(2) and D(3) receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D(2)/D(3)-dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. It may also have 5-ht7 antagonistic effect, useful in depression treatment.
n3:synonym
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide Amisulpridum Aminosultopride Amisulprida
n3:toxicity
Overdoses of amisulpride have been linked with torsades de pointes.
n3:proteinBinding
Low (17%)
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Amisulpride.htm
n18:hasConcept
n19:M0058773
n3:IUPAC-Name
n4:271B4BEC-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4BF2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4BF1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4BEE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4BEF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4BF0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4BEA-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4C03-363D-11E5-9242-09173F13E4C5 n4:271B4BE8-363D-11E5-9242-09173F13E4C5 n4:271B4BEB-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4BE9-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4C04-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:N05AL05
n3:H-Bond-Acceptor-Count
n4:271B4BF8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4BF9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4BF3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4BF4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4BF6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4BF5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4BF7-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability is 48% following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
53583-79-2
n3:category
n3:Bioavailability
n4:271B4BFE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4C00-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4C01-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4C02-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4BFD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4BFC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4BFF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4BED-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4BFA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4BFB-363D-11E5-9242-09173F13E4C5